Developer docs
API playgroundTry for free, no card

Search company profiles

Closed Loop Medicine

Full company profile

uuid0000cw8

Namestring
Closed Loop Medicine
Legal namestring
Closed Loop Medicine Ltd
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Closed Loop Medicine is a UK-based health technology company founded in 2017 that develops personalized drug-plus-software combination products, pairing pharmaceutical therapies with proprietary Software as a Medical Device (SaMD) to enable AI-driven adaptive dosing. The company's underlying platform combines machine learning with pharmacokinetic and pharmacodynamic (PK/PD) models to calculate individualized doses for each patient, with a closed-loop feedback architecture that returns patient response data to the platform for continuous refinement. The product portfolio includes WeDosify, a commercially launched GLP-1 titration platform deployed to US clinicians; CLM-IN01, a drug-device combination product for insomnia that has secured UKCA marking and CE designation; and CLM-HT01, a single-label combination product integrating SaMD with amlodipine for hypertension management.

The company operates a hybrid business model that monetizes its platform through two complementary streams: licensing and royalty-style arrangements with pharmaceutical partners for co-developed combination products (notably a strategic partnership with Teva UK announced in March 2024), and a recurring SaaS revenue stream from WeDosify deployments to healthcare providers, telehealth companies, and health systems, with initial US deployment at Amarillo Premier Research in Texas. Primary customers are pharmaceutical companies, payors, and healthcare providers, with the end beneficiary being patients with chronic conditions such as obesity, hypertension, and insomnia. The company's commercial and clinical positioning is supported by 4 granted patents and over 30 pending applications, ISO 27001:2022 certification, regulatory milestones across the UK and EU, recognition on TIME's 2025 World's Top HealthTech Companies list, and membership in the NVIDIA Inception Program.

Closed Loop Medicine is led by CEO Kate Woolland, who was appointed in May 2025 succeeding co-founder Hakim Yadi, with co-founder Dr Paul Goldsmith serving as Chief Medical & Innovation Officer and President. Luba Greenwood serves as Chair of the Board (appointed September 2024). The company is headquartered in Cambridge at Babraham Research Campus with a registered office in Altrincham, UK, and claims a global operating footprint spanning the UK, USA, Canada, Australia, Mexico, Israel, and Taiwan.

Short descriptiontext

Closed Loop Medicine is a UK healthtech company developing AI-driven personalized drug-plus-software combination products, including WeDosify (GLP-1 dosing, US-launched September 2025), CLM-IN01 (insomnia), and CLM-HT01 (hypertension). It serves pharmaceutical companies, payors, and healthcare providers via licensing partnerships and a SaaS dosing platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
personalized medicine software, AI dosing optimization, digital therapeutics platform, combination drug-device products, GLP-1 titration tools
Industry2 codes
PRIMARYHLACANAA
Condition-specific Digital Therapeutics (DTx)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Software Publishers5132
SIC code2 codes
  • Services-Prepackaged Software7372
  • Surgical & Medical Instruments & Apparatus3841
Product category
Digital Therapeutics Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Partnership Products
TypeLicensing Royalties
Description

CLM partners with pharmaceutical companies to create patent-protected single prescription combination products. Each product is individually tailored to disease use settings and built using CLM's proprietary platform of intellectual property, regulatory expertise, and clinical evidence.

closedloopmedicine.com
2SaaS Dosing Platform (WeDosify)
TypeSubscription Recurring
Description

WeDosify enables clinicians to personalize GLP-1 titration at scale. The platform is being deployed to healthcare providers, telehealth companies, and health systems to make informed titration decisions, representing a commercial software/platform revenue stream.

closedloopmedicine.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1WeDosify
Description

A GLP-1 dosing platform that enables clinicians to personalize GLP-1 titration at scale, delivering data-driven, adaptive dosing recommendations to improve GLP-1 adherence.

closedloopmedicine.com
Core offering1 text field

Closed Loop Medicine (CLM) develops an AI-based adaptive dosing platform that combines drug therapy with digital care solutions to create patent-protected single-prescription combination drug-device products. The company delivers software-enabled precision dosing across therapy areas such as insomnia (CLM-IN01), hypertension (CLM-HT01), and GLP-1 obesity management (WeDosify), with clinical evidence drawn from 29 studies and 15,000+ patient profiles.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 91% of GLP-1 patients would be more likely to stay on treatment with WeDosify support
+2 more records
Product overview1 text field

Closed Loop Medicine is a health technology company that delivers personalized treatment solutions through a proprietary platform combining dose-optimized drug therapy with digital care. The company's portfolio includes WeDosify (a commercially available GLP-1 personalized dosing platform), CLM-IN01 (an insomnia drug-device combination product in regulatory development), and CLM-HT01 (a hypertension product integrating proprietary SaMD with amlodipine). The platform leverages AI-driven adaptive dosing algorithms, pharmacokinetic/pharmacodynamic modeling, and closed-loop feedback systems to enable genuine personalization at scale.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-26
Description

Strategic partnership announced March 26, 2024 to advance development of personalised medicines. Teva UK and Closed Loop Medicine are collaborating to develop personalized treatment solutions combining drug therapy with digital care.

2Orient Pharma
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Shown as a partner logo on CLM's website, indicating some form of collaboration or partnership relationship.

closedloopmedicine.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical partnership with Queen Mary University London for patient-centric healthcare innovation linking traditional therapeutics, medical devices and digital health. Dr David Collier serves as Clinical Director.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with uMed to combine their unique approach to clinical trial delivery with CLM's technology for decentralized clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CPI collaborated with CLM on patient-centric healthcare innovation linking traditional therapeutics, medical devices and digital health. CPI provides core strengths in healthcare innovation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Click Therapeutics develops prescription digital therapeutics and drug-device-digital combination products (e.g., with Otsuka for depression). Closest direct peer given overlapping combination-product model and clinical SaaS delivery.

TypeDirect peer
Description

Akili Interactive is a prescription digital therapeutic company (EndeavorRx) cleared by FDA as SaMD. Directly comparable as a DTx/SaMD publisher targeting clinician-prescribed software for chronic conditions.

TypeDirect peer
Description

WellDoc develops BlueStar, an FDA-cleared digital therapeutic for diabetes management that combines medication and behavioral coaching. Closely aligned to CLM's drug + digital combination approach in chronic disease dosing.

TypeDirect peer
Description

DoseMeRx is a precision dosing software platform that uses pharmacokinetic models and Bayesian algorithms to optimize medication dosing for individual patients. Highly comparable to CLM's AI-driven adaptive dosing approach.

TypeDirect peer
Description

InsightRX provides precision dosing software leveraging PK/PD modeling and Bayesian forecasting for individualized drug dosing. Operates in the same personalized dosing category as CLM with comparable technology stack.

6Biofourmis
TypeDirect peer
Description

Biofourmis combines remote patient monitoring with AI-driven analytics for personalized therapy management in chronic disease. Comparable as a combination-product platform using sensor data + AI to optimize treatment.

TypeDirect peer
Description

Voluntis (now part of Aptar Pharma) develops companion digital therapeutics for oncology and diabetes medications. Closely aligned as a prescription SaMD paired with pharmaceutical products.

8Ro
TypeEmerging player
Description

Ro is a direct-to-patient telehealth platform that prescribes GLP-1 therapies and may bundle personalized dosing support. Emerging competitor in the GLP-1 dosing support space that CLM targets with WeDosify.

TypeBroad incumbent
Description

Hims & Hers is a large telehealth platform that prescribes GLP-1 weight-loss drugs and is building proprietary dosing and care tools. A broad incumbent in personalized GLP-1 care delivery that could subsume or compete with WeDosify.

TypeEmerging player
Description

Sidekick Health is a digital therapeutics company offering prescription digital therapeutics for chronic disease management. Comparable as a DTx platform pursuing pharma partnerships and combination-product positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Closed Loop Medicine

Digital Therapeutics Softwareclosedloopmedicine.com

Closed Loop Medicine is a UK healthtech company developing AI-driven personalized drug-plus-software combination products, including WeDosify (GLP-1 dosing, US-launched September 2025), CLM-IN01 (insomnia), and CLM-HT01 (hypertension). It serves pharmaceutical companies, payors, and healthcare providers via licensing partnerships and a SaaS dosing platform.

What Closed Loop Medicine does

Closed Loop Medicine is a UK-based health technology company founded in 2017 that develops personalized drug-plus-software combination products, pairing pharmaceutical therapies with proprietary Software as a Medical Device (SaMD) to enable AI-driven adaptive dosing. The company's underlying platform combines machine learning with pharmacokinetic and pharmacodynamic (PK/PD) models to calculate individualized doses for each patient, with a closed-loop feedback architecture that returns patient response data to the platform for continuous refinement. The product portfolio includes WeDosify, a commercially launched GLP-1 titration platform deployed to US clinicians; CLM-IN01, a drug-device combination product for insomnia that has secured UKCA marking and CE designation; and CLM-HT01, a single-label combination product integrating SaMD with amlodipine for hypertension management.

The company operates a hybrid business model that monetizes its platform through two complementary streams: licensing and royalty-style arrangements with pharmaceutical partners for co-developed combination products (notably a strategic partnership with Teva UK announced in March 2024), and a recurring SaaS revenue stream from WeDosify deployments to healthcare providers, telehealth companies, and health systems, with initial US deployment at Amarillo Premier Research in Texas. Primary customers are pharmaceutical companies, payors, and healthcare providers, with the end beneficiary being patients with chronic conditions such as obesity, hypertension, and insomnia. The company's commercial and clinical positioning is supported by 4 granted patents and over 30 pending applications, ISO 27001:2022 certification, regulatory milestones across the UK and EU, recognition on TIME's 2025 World's Top HealthTech Companies list, and membership in the NVIDIA Inception Program.

Closed Loop Medicine is led by CEO Kate Woolland, who was appointed in May 2025 succeeding co-founder Hakim Yadi, with co-founder Dr Paul Goldsmith serving as Chief Medical & Innovation Officer and President. Luba Greenwood serves as Chair of the Board (appointed September 2024). The company is headquartered in Cambridge at Babraham Research Campus with a registered office in Altrincham, UK, and claims a global operating footprint spanning the UK, USA, Canada, Australia, Mexico, Israel, and Taiwan.

Closed Loop Medicine firmographics

Firmographics
Name
Closed Loop Medicine
Legal name
Closed Loop Medicine Ltd
Website
https://closedloopmedicine.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Closed Loop Medicine is a UK healthtech company developing AI-driven personalized drug-plus-software combination products, including WeDosify (GLP-1 dosing, US-launched September 2025), CLM-IN01 (insomnia), and CLM-HT01 (hypertension). It serves pharmaceutical companies, payors, and healthcare providers via licensing partnerships and a SaaS dosing platform.
Ownership category
akta.pro rank

Closed Loop Medicine industry classification

Industry
Product category
Digital Therapeutics Software
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAA
Condition-specific Digital Therapeutics (DTx)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Personalized medicine software
  • AI dosing optimization
  • Digital therapeutics platform
  • Combination drug-device products
  • GLP-1 titration tools

Where Closed Loop Medicine is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Closed Loop Medicine business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Partnership Products: CLM partners with pharmaceutical companies to create patent-protected single prescription combination products. Each product is individually tailored to disease use settings and built using CLM's proprietary platform of intellectual property, regulatory expertise, and clinical evidence.
  2. SaaS Dosing Platform (WeDosify): WeDosify enables clinicians to personalize GLP-1 titration at scale. The platform is being deployed to healthcare providers, telehealth companies, and health systems to make informed titration decisions, representing a commercial software/platform revenue stream.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Closed Loop Medicine product offering

Product offering

Core offering

Closed Loop Medicine (CLM) develops an AI-based adaptive dosing platform that combines drug therapy with digital care solutions to create patent-protected single-prescription combination drug-device products. The company delivers software-enabled precision dosing across therapy areas such as insomnia (CLM-IN01), hypertension (CLM-HT01), and GLP-1 obesity management (WeDosify), with clinical evidence drawn from 29 studies and 15,000+ patient profiles.

Product overview

Closed Loop Medicine is a health technology company that delivers personalized treatment solutions through a proprietary platform combining dose-optimized drug therapy with digital care. The company's portfolio includes WeDosify (a commercially available GLP-1 personalized dosing platform), CLM-IN01 (an insomnia drug-device combination product in regulatory development), and CLM-HT01 (a hypertension product integrating proprietary SaMD with amlodipine). The platform leverages AI-driven adaptive dosing algorithms, pharmacokinetic/pharmacodynamic modeling, and closed-loop feedback systems to enable genuine personalization at scale.

Differentiator

Problem solved

Functional benefit

Brands

  • WeDosify: A GLP-1 dosing platform that enables clinicians to personalize GLP-1 titration at scale, delivering data-driven, adaptive dosing recommendations to improve GLP-1 adherence.

Quantifiable outcome

  • 91% of GLP-1 patients would be more likely to stay on treatment with WeDosify support
  • +2 more outcomes

Companies that use Closed Loop Medicine

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Closed Loop Medicine technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Closed Loop Medicine partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Teva UKcoreStrategic or Co-development Partner · 26 March 2024Strategic partnership announced March 26, 2024 to advance development of personalised medicines. Teva UK and Closed Loop Medicine are collaborating to develop personalized treatment solutions combining drug therapy with digital care.
  • Orient PharmaminorStrategic or Co-development PartnerShown as a partner logo on CLM's website, indicating some form of collaboration or partnership relationship.
  • Queen Mary University LondoncoreStrategic or Co-development PartnerClinical partnership with Queen Mary University London for patient-centric healthcare innovation linking traditional therapeutics, medical devices and digital health. Dr David Collier serves as Clinical Director.
  • uMedcoreStrategic or Co-development PartnerPartnership with uMed to combine their unique approach to clinical trial delivery with CLM's technology for decentralized clinical trials.
  • CPI (Centre for Process Innovation)coreStrategic or Co-development PartnerCPI collaborated with CLM on patient-centric healthcare innovation linking traditional therapeutics, medical devices and digital health. CPI provides core strengths in healthcare innovation.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Closed Loop Medicine competitors and assessment

Company assessment

Direct peers

  • Click Therapeutics: Click Therapeutics develops prescription digital therapeutics and drug-device-digital combination products (e.g., with Otsuka for depression). Closest direct peer given overlapping combination-product model and clinical SaaS delivery.
  • Akili Interactive: Akili Interactive is a prescription digital therapeutic company (EndeavorRx) cleared by FDA as SaMD. Directly comparable as a DTx/SaMD publisher targeting clinician-prescribed software for chronic conditions.
  • WellDoc: WellDoc develops BlueStar, an FDA-cleared digital therapeutic for diabetes management that combines medication and behavioral coaching. Closely aligned to CLM's drug + digital combination approach in chronic disease dosing.
  • DoseMeRx: DoseMeRx is a precision dosing software platform that uses pharmacokinetic models and Bayesian algorithms to optimize medication dosing for individual patients. Highly comparable to CLM's AI-driven adaptive dosing approach.
  • InsightRX: InsightRX provides precision dosing software leveraging PK/PD modeling and Bayesian forecasting for individualized drug dosing. Operates in the same personalized dosing category as CLM with comparable technology stack.
  • Biofourmis: Biofourmis combines remote patient monitoring with AI-driven analytics for personalized therapy management in chronic disease. Comparable as a combination-product platform using sensor data + AI to optimize treatment.
  • Voluntis (Aptar Pharma): Voluntis (now part of Aptar Pharma) develops companion digital therapeutics for oncology and diabetes medications. Closely aligned as a prescription SaMD paired with pharmaceutical products.

Emerging players

  • Ro: Ro is a direct-to-patient telehealth platform that prescribes GLP-1 therapies and may bundle personalized dosing support. Emerging competitor in the GLP-1 dosing support space that CLM targets with WeDosify.
  • Sidekick Health: Sidekick Health is a digital therapeutics company offering prescription digital therapeutics for chronic disease management. Comparable as a DTx platform pursuing pharma partnerships and combination-product positioning.

Broad incumbents

  • Hims & Hers Health: Hims & Hers is a large telehealth platform that prescribes GLP-1 weight-loss drugs and is building proprietary dosing and care tools. A broad incumbent in personalized GLP-1 care delivery that could subsume or compete with WeDosify.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Closed Loop Medicine social profiles

Digital presence

Closed Loop Medicine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Closed Loop Medicine leadership team

Management profile

Number of profiles

Profiles7 records

Closed Loop Medicine funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Closed Loop Medicine M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Closed Loop Medicine

What does Closed Loop Medicine do?

Closed Loop Medicine (CLM) develops an AI-based adaptive dosing platform that combines drug therapy with digital care solutions to create patent-protected single-prescription combination drug-device products. The company delivers software-enabled precision dosing across therapy areas such as insomnia (CLM-IN01), hypertension (CLM-HT01), and GLP-1 obesity management (WeDosify), with clinical evidence drawn from 29 studies and 15,000+ patient profiles.

Is Closed Loop Medicine a public or private company?

Closed Loop Medicine is a private company. It is classified as venture growth investor backed and is currently operating.

When was Closed Loop Medicine founded?

Closed Loop Medicine was founded in 2017. It employs 1 to 10 people.

Where is Closed Loop Medicine based?

Closed Loop Medicine is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Closed Loop Medicine make money?

Two revenue lines are on record. Pharmaceutical Partnership Products are the primary driver. The others are saaS Dosing Platform (WeDosify).

Who are Closed Loop Medicine's main competitors?

Direct peers on record are Click Therapeutics, Akili Interactive, WellDoc, DoseMeRx, InsightRX, Biofourmis and Voluntis (Aptar Pharma). Emerging players are Ro and Sidekick Health. Hims & Hers Health is listed as a broad incumbent.

Does Closed Loop Medicine have an API?

No public API is recorded for Closed Loop Medicine.

What industry is Closed Loop Medicine in?

Closed Loop Medicine's product category is Digital Therapeutics Software. Its primary akta.pro industry code is HLACANAA, Condition-specific Digital Therapeutics (DTx), with a secondary code of HLACANAH, Therapeutic Companion Apps (Drug-Device-Digital Combination). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comLeading Companies Fueling Growth and Innovation in the Drug Device Combination MarketThe Business Research Company published a market report projecting the global drug device combination market to reach $249.33 billion by 2030, growing at a compound annual growth rate of 11.5%. Key growth drivers include rising adoption of personalized medicine, increased demand for connected medical devices, and expanding home-based drug delivery options. In May 2023, UK-based TechBio firm Closed Loop Medicine Ltd. partnered with UK pharmaceutical company Pharmanovia to advance precision medicine using genetic and molecular profiling for tailored drug combinations.News-MedicalClosed Loop Medicine launches first personalized GLP-1 dosing platform In U.S.Closed Loop Medicine Ltd launched WeDosify, a personalized GLP-1 titration platform, in the U.S. as its first commercially available product, targeting the high dropout rate of 44-60% among GLP-1 therapy patients within 12 months due to side effects and lack of individualized support. The platform draws on 29 clinical studies and 15,000+ patient profiles with pharmacokinetic modeling to provide real-time personalized dosing recommendations for healthcare providers and health systems. Amarillo Premier Research in Texas is the first clinical site beginning use of the platform this week.PharmiWeb.comClosed Loop Medicine Launches First Personalized GLP-1 Dosing Platform in U.S.Closed Loop Medicine launched WeDosify in the U.S., a platform for personalized GLP-1 dosing. The platform draws on 29 studies and 15,000+ patient profiles, and 91% of surveyed patients said they'd stay on treatment with its support. Amarillo Premier Research in Texas began using it this week.BioSpaceOpinion: Drugs Are Becoming ‘Smarter.’ Here’s HowThe author argues that pharma pipelines will soon be digitized, with each drug paired to a software-enhanced version for personalized treatment. The FDA's PDURS guidance enables added benefit claims for drug-software combinations, and partnerships like Teva and Closed Loop Medicine are already underway. The author predicts this will become standard care.News-MedicalTeva UK and Closed Loop Medicine announce strategic partnership to advance development of personalised medicinesTeva UK and Closed Loop Medicine announced a strategic partnership to develop personalized medicines using Closed Loop Medicine's software as a medical device (SaMD) platform. The partnership aims to combine dose-optimized drug therapy with digital care, with recent trial results for CLM-HT01 showing improved blood pressure control and adherence. The collaboration seeks to integrate real-world data to personalize dosing.Business Wire BlogTeva UK and Closed Loop Medicine Announce Strategic Partnership to Advance Development of Personalised MedicinesTeva UK and Closed Loop Medicine announced a strategic partnership to advance personalised medicines using Closed Loop Medicine's SaMD platform. The collaboration aims to combine dose-optimised drug therapy with digital care, citing clinical trial results for CLM-HT01. The partnership seeks to improve patient outcomes and reduce adverse drug reactions.ClosedloopmedicineSifted: 11 digital therapeutics startups to watch, according to VCsA Sifted report highlights digital therapeutics startups attracting VC interest, including Closed Loop Medicine, which is building software therapy products to optimise prescription drug dosing and deliver personalised therapies. The company will initially target chronic conditions such as insomnia and hypertension, citing positive pilot data and co-development agreements with pharma firms.Tech.euClosed Loop Medicine advances smartphone-enabled precision medicineClosed Loop Medicine published a peer-reviewed study in the Journal of the American Heart Association on its CLM-HT01 precision dosing system for amlodipine in hypertension. The PERSONAL-CovidBP trial showed rapid blood pressure control and high adherence, with no discontinuations due to intolerance. The company plans to apply these learnings to other therapeutic areas.BioSpaceClosed Loop Medicine and Pharmanovia enter a co-development partnership for precision medicine combination therapeuticsClosed Loop Medicine and Pharmanovia announced a global co-development partnership to combine their drug and software therapy for hypertension. The partnership will initially focus on a first-line anti-hypertensive in the UK, with phased global rollout. The companies aim to improve adherence and patient outcomes.dlvr.itPharmanovia and Closed Loop Medicine in precision medicine partnershipPharmanovia and Closed Loop Medicine announced a worldwide co-development collaboration to combine dosing optimization software with anti-hypertensive drugs. The UK-first launch will precede a global rollout, aiming to improve blood pressure control and reduce side effects. The partnership targets hypertension, which costs the NHS over £2.1bn annually.